Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Resources

The latest in from biologics discovery and development through to production and supply chain management.

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Read Now
Proteins & Antibodies

Interview with Andrew Brown, Head of Process Development Sciences at Lonza

Andrew Brown, Head of Process Development Sciences at Lonza, talks about Lonza's approach to process development.
Read More
Peptides

AI-Discovered Peptide has Dramatic Impact on Muscle Conditioning

Are plant-derived peptides set to replace animal proteins as the go-to supplement for muscle conditioning?
Read More
Oligonucleotides

The Complex Case of Antisense Oligonucleotides

We gain a glimpse into what the landscape of antisense oligonucleotides looks like today, from computational representations to protein purification.
Read More
Vaccines

MIT Team Create AI-Generated Universal COVID Vaccine

New COVID variants are still a significant risk; but could an AI-generated universal COVID vaccine be the key to overcoming this?
Read More
Proteins & Antibodies

How AI is Changing the Game for Protein Design

Researchers at the University of Washington have succeeded in using machine learning to synthesise artificial enzymes which are actually functional in cells.
Read More
Proteins & Antibodies

Computational Tools and AI/ML for Antibody Engineering

Opinion leaders from Merck and AbbVie discuss how antibody-based molecular engineering is developing with new AI/ML technologies.
Read More
Biosimilars & Biobetters

Biocon’s Biosimilar Difficulties: Successive FDA Rejections Don’t Inspire Hope

Biocon suffer another FDA rejection due to data and manufacturing concerns, this time for their bevacizumab biosimilar.
Read More
Vaccines

The EMA’s Vaccines Working Party: The New Authority on Vaccines

The Vaccines Working Party was established last year by the EMA, but what are its main tasks, and how are they looking to achieve them?
Read More
Proteins & Antibodies

POLIVY vs ODAC: Can the Cancer Drug Score Another Indication?

The Oncologic Drugs Advisory Committee are preparing to weigh in on whether the FDA should grant another indication for Roche’s POLIVY.
Read More
Proteins & Antibodies

No More Hold-Ups: FDA Lifts Hold on Parkinson’s Drug

The FDA has repealed the hold placed on clinical trials for the Parkinson’s drug IkT-148009, which began in November.
Read More
Vaccines

The Race for an RSV Vaccine Approval

Things are heating up in the race to pinch the first FDA approval of an RSV vaccine, as Moderna joins Pfizer and GSK in the running.
Read More
Proteins & Antibodies

FDA Grant Approval for Alzheimer's Drug Leqembi

The US regulators have approved Eisai and Biogen’s Alzheimer’s drug, lecanemab, a “landmark” moment for the disease.
Read More

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things biologics